Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect

Experimental Gerontology

Volumn 35, Issue 8, 2000, Pages 1017-1024

  Bour, A M J J ^a   Westendorp, R G J ^a   Laterveer, J C ^a   Bollen, E L E M ^a   Remarque, E J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Cytokines; Indomethacin; Prostaglandin; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; CYTOKINE; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; THROMBIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD; BRAIN PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; INFLAMMATION; MULTIINFARCT DEMENTIA; NEGATIVE FEEDBACK; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CYTOKINES; DINOPROSTONE; FEMALE; HUMANS; INDOMETHACIN; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; THROMBIN;

EID: 0033730758     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0531-5565(00)00128-5     Document Type: Article

References (26)

1. Cytokines in Alzheimer's disease
2. Expression and regulation of cyclooxygenase-2 in rat microglia
3. Persistent inflammatory response in stroke survivors
4. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post- mortem astrocytes: the involvement of prostaglandin E2
5. Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production
6. Interleukin-1 and interleukin-1 antagonism
7. Biologic basis for interleukin-1 in disease
8. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes
9. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution
10. The effects of anti-inflammatory and antiallergic drugs on the release of IL-1 beta and TNF-alpha in the human whole blood assay
11. Interleukin-6 is present in the early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
12. Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options
13. The proinflammatory cytokine response to coagulation and endotoxin in whole blood
14. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation
15. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains
16. Increased thromboxane biosynthesis is associated with poststroke dementia
17. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies
18. Role of IL-10 in the crossregulation of prostaglandins and cytokines in monocytes
19. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease
20. Clinical trial of indomethacin in Alzheimer's disease
21. Cytokines and the nervous system II: actions and mechanisms of action
22. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes
23. Risk of Alzheimer's disease and duration of NSAID use
24. New insights into the biology of the acute phase response
25. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans
26. Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase-1 and -2